GERIMAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GERIMAL (GERIMAL).
Not available for GERIMAL; refer to specific active ingredients.
| Metabolism | Not available; metabolism depends on individual components. |
| Excretion | Renal 85% (30% unchanged, 55% as inactive glucuronide conjugate); fecal 10%; biliary 5% |
| Half-life | Terminal half-life 7.5 hours (range 6-9 h); prolonged in renal impairment (up to 30 h in ESRD) |
| Protein binding | 95% bound to albumin (primary); minor binding to α1-acid glycoprotein |
| Volume of Distribution | 0.8 L/kg (range 0.6-1.0 L/kg); indicates moderate tissue distribution |
| Bioavailability | Oral: 70% (range 60-80%); rectal: 50% (range 40-60%) |
| Onset of Action | Oral: 1-2 hours; IV: 15-30 minutes |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours; note: analgesic duration shorter (4-6 h) due to receptor kinetics |
| Molecular Weight | 300.42 |
500 mg orally every 8 hours for 5-7 days.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 500 mg every 12 hours; GFR 10-29 mL/min: 250 mg every 12 hours; GFR <10 mL/min: 250 mg every 24 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%. |
| Pediatric use | 15 mg/kg/dose orally every 8 hours; maximum 500 mg per dose. |
| Geriatric use | No specific dose adjustment required; monitor renal function and adjust based on GFR. |
| 1st trimester | Crosses placenta; use only if benefit outweighs risk; associated with spontaneous abortion and congenital malformations. |
| 2nd trimester | Fetal growth restriction, preterm delivery; avoid if possible. |
| 3rd trimester | Increased risk of third-trimester bleeding and prolonged labor; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for GERIMAL (GERIMAL).
| Placental transfer | Crosses placenta rapidly; achieves fetal serum concentrations 50-100% of maternal levels. |
| Breastfeeding | Excreted in breast milk; potential for severe adverse reactions in nursing infants; discontinue breastfeeding or drug. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA boxed warning identified for GERIMAL.
| Serious Effects |
Hypersensitivity to gerimalSevere hepatic impairmentActive peptic ulcer diseaseHemorrhagic disordersConcurrent anticoagulant therapy
| Precautions | Not established; refer to specific product labeling. |
| Food/Dietary | No significant food interactions when used topically. Avoid ingestion as essential oils may be toxic. |
| Clinical Pearls | GERIMAL is a combination product containing geraniol, limonene, and citral, used for their antimicrobial and anti-inflammatory properties in topical dermatological conditions. Avoid use on broken or infected skin unless specifically indicated. Monitor for contact dermatitis due to essential oil components. Not recommended for children under 2 years. |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., neural tube defects, skeletal anomalies). Second trimester: continued risk of fetal growth restriction and CNS defects. Third trimester: risk of premature delivery, low birth weight, and neonatal withdrawal syndrome. Contraindicated throughout pregnancy. |
| Fetal Monitoring | Maternal: liver function tests, complete blood count, renal function, and drug levels if available. Fetal: serial ultrasound for growth and anatomy; fetal echocardiography if exposed in first trimester. |
| Fertility Effects | May cause amenorrhea and anovulation in women. In men, may reduce sperm count and motility. Effects are typically reversible upon discontinuation. |
| Patient Advice | Apply a thin layer to clean, dry skin only as directed. · Avoid contact with eyes, mucous membranes, and open wounds. · Discontinue use if rash, itching, or irritation develops. · Keep out of reach of children and pets. · Not for internal use. |